An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: The REVIVE trial

Thrombosis Research

Volumn 109, Issue 2-3, 2003, Pages 85-92

  Massicotte, Patricia ^a   Julian, Jim A ^b   Gent, Michael ^b   Shields, Karen ^b   Marzinotto, Velma ^a   Szechtman, Barbara ^b   Andrew, Maureen ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b NONE

Author keywords

Pediatrics; Venous thromboembolism

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; WARFARIN;

ADOLESCENT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE BLIND PROCEDURE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 12444288449     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00059-8     Document Type: Article

References (14)

1. Andrew M., Ofosu F., Schmidt B.et al. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb. Res. 52(6):1988 (Dec.);517-527.
2. Baglin T.P. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J. Clin. Pathol. 54(4):2001 (Apr.);272-274.
3. Andrew M., Marzinotto V., Massicotte P.et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr. Res. 35(1):1994 (Jan.);78-83.
4. Streif W., Andrew M., Marzinotto V.et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 94(9):1999 (Nov.);3007-3014.
5. Massicotte P., Julian J., Webber C., Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy. Thromb. Haemost., Suppl. 1333a:1999.
6. Mammen E.F. Low molecular weight heparins and heparin-induced thrombocytopenia. Clin. Appl. Thromb./Hemost. 5(Suppl. 1):1999 (Oct.);S72-S75.
7. Bhandari M., Hirsh J., Weitz J.I.et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb. Haemost. 80(3):1998 (Sept.);413-417.
8. Muir J.M., Hirsh J., Weitz J.I.et al. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood. 89(9):1997 (May);3236-3242.
9. Hirsh J., Warkentin T.E., Shaughnessy S.G.et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119(Suppl. 1):2001 (Jan.);64S-94S.
10. Massicotte M.P., Dix D., Monagle P.et al. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J. Pediatr. 133(6):1998 (Dec.);770-776.
11. Andrew M., David M., Adams M.et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 83(5):1994 (Mar.);1251-1257.
12. Schmidt B., Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics. 96(5 Pt 1):1995 (Nov.);939-943.
13. Monagle P., Adams M., Mahoney M.et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr. Res. 47(6):2000 (June);763-766.
14. Dolovich L.R., Ginsberg J.S., Douketis J.D.et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. 160(2):2000 (Jan.);181-188.